ArticleMitochondrion2013
RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy.
Article in Mitochondrion, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Crosslink between mutations in mitochondrial genes and brain disorders: implications for mitochondrial-targeted therapeutic interventions.Neural regeneration research · 2023Review
- Article
- Advances in drug therapy for mitochondrial diseases.Annals of translational medicine · 2020Review
- Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure.CNS neuroscience & therapeutics · 2019Review
- Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats.Neurotoxicity research · 2019Article
- Circulating HDL levels control hypothalamic astrogliosis via apoA-I.Journal of lipid research · 2018Article
- Emerging therapies for mitochondrial diseases.Essays in biochemistry · 2018Review
- Article
- The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice.Frontiers in pharmacology · 2018Article
- Therapies for mitochondrial diseases and current clinical trials.Molecular genetics and metabolism · 2017Review
- The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.Orphanet journal of rare diseases · 2017Article
- The Bioinformatic Analysis of the Dysregulated Genes and MicroRNAs in Entorhinal Cortex, Hippocampus, and Blood for Alzheimer's Disease.BioMed research international · 2017Article
- Mitochondria as a therapeutic target in Alzheimer's disease.Genes & diseases · 2016Review
- Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Human molecular genetics · 2016Article
- Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.Molecular neurodegeneration · 2016Article
- Mitochondrial cytochrome c oxidase deficiency.Clinical science (London, England : 1979) · 2016Review
- Mitochondrial Quality Control as a Therapeutic Target.Pharmacological reviews · 2016Review
- Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.Mitochondrion · 2015Review
- MTO1 mediates tissue specificity of OXPHOS defects via tRNA modification and translation optimization, which can be bypassed by dietary intervention.Human molecular genetics · 2015Article
- Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease.Cell biochemistry and biophysics · 2014Review
Corrections and comments
- Retraction · 2017-06-15Falsification/Fabrication of Image · Investigation by Company/Institution · Investigation by Third Party · Manipulation of Images · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · · Misconduct finding against Tina Wenz: http://www.portal.uni-koeln.de/9015.html?&L=13&tx_news_pi1%5Bnews%5D=4335&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=1deb8399d7f796d65ca9f6ae4764a1ce
- Retracted
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This retraction was suggested by the University of Cologne Investigation committee and seconded by the authors who the journal was able to contact (Wenz, T., Dillon, L., Diaz, F., Hida, A., and Moraes, C.T.). Following an investigation of the last author, Dr. Tina Wenz, by the University of Cologne, Germany, the university determined that data presented in this article have been inappropriately manipulated https://www.portal.uni-koeln.de/9015.html?&tx_news_pi1%5Bnews%5D=4335&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=1deb8399d7f796d65ca9f6ae4764a1ce. Specifically, western blot images in Figure 5F (tubulin in cortex), 2F (COXI in hippocampus) and 3B (Sod2 in hippocampus) were re-used from an earlier article published elsewhere [Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging" Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, and Moraes CT. Proc Natl Acad Sci U S A. 2009;106:20405-10, doi: 10.1073/pnas.0911570106] representing different experimental findings. Therefore, whether or not the main conclusions are still valid, the authors request retraction of this publication because the scientific integrity of the study was compromised. The authors sincerely apologize to the scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.